Viridian Therapeutics to Webcast First Quarter 2024 Financial Results on May 8, 2024
29 Aprile 2024 - 2:00PM
Business Wire
Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology
company focused on discovering and developing potential
best-in-class medicines for serious and rare diseases, today
announced it will host a webcast and conference call on Wednesday,
May 8 at 8:00 a.m. ET to discuss its first quarter 2024 financial
results and recent business highlights.
The webcast can be accessed under “Events and Presentations” on
the Investors section of the Viridian website at
viridiantherapeutics.com. To participate in the conference call,
please dial 800-715-9871 (domestic) or 646-307-1963 (international)
and reference code 7373356. A replay of the webcast will be
available following the completion of the event.
About Viridian Therapeutics
Viridian is a biopharmaceutical company focused on engineering
and developing potential best-in-class medicines for patients with
serious and rare diseases. Viridian’s expertise in antibody
discovery and protein engineering enables the development of
differentiated therapeutic candidates for previously validated drug
targets in commercially established disease areas.
Viridian is advancing multiple candidates in the clinic for the
treatment of patients with thyroid eye disease (TED). The company
is conducting two global Phase 3 clinical trials (THRIVE and
THRIVE-2) to evaluate the safety and efficacy of VRDN-001 in
patients with active and chronic TED. Viridian’s goal is to advance
VRDN-001 as a potential best-in-class intravenous therapy followed
by VRDN-003 as a potential first- and best-in-class subcutaneous
therapy for the treatment of TED.
In addition to its TED portfolio, Viridian is advancing a novel
portfolio of neonatal Fc receptor (FcRn) inhibitors, including
VRDN-006 and VRDN-008, which has the potential to be developed in
multiple autoimmune diseases.
Viridian is based in Waltham, Massachusetts. For more
information, please visit www.viridiantherapeutics.com. Follow
Viridian on LinkedIn and X.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240428139202/en/
Louisa Stone, 617-272-4604 Manager, Investor Relations
IR@viridiantherapeutics.com
Grafico Azioni Viridian Therapeutics (NASDAQ:VRDN)
Storico
Da Ott 2024 a Nov 2024
Grafico Azioni Viridian Therapeutics (NASDAQ:VRDN)
Storico
Da Nov 2023 a Nov 2024
